Medindia

X

Peripheral Arterial Disease Therapeutics Market is forecast to Show Modest Growth until 2016

Tuesday, February 16, 2010 Research News J E 4
Advertisement
Peripheral Arterial Disease (PAD) - Drug Pipeline Analysis and Market Forecasts to 2016 The report provides key data information and analysis on the global peripheral arterial disease market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009 and forecasts for seven years to 2016. The report provides coverage of the market landscape market drivers and restraints and an in-depth pipeline analysis. The current competitive landscape is also analyzed and the unmet need or commercial opportunity of the market is calculated. The pipeline analysis covers molecules across all phases of clinical development and provides an overview of the developing trends among pipeline molecules as well as an insight into the most promising pipeline drugs supplemented with key company profiles. By considering the current competition in the market and the prospects of the pipeline molecules the resulting implications for the future market competition is also outlined. ( http://www.bharatbook.com/detail.asp?id=132247&rt=Peripheral-Arterial-Disease-PAD-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html ) The PAD Therapeutics Market is forecast to Show Modest Growth until 2016 The global peripheral arterial disease (PAD) therapeutics market was worth approximately $897m in 2009. In 2001 the market was valued at $568m and it grew at an approximate CAGR of 5.9% between 2001 and 2009. The global PAD therapeutics market is expected to reach $1.3 billion by 2016 after growing at a CAGR of 6.1% between 2001 and 2016. The primary factor contributing to the increase in growth over the forecast period is the increase in disease incidence. Presently the therapeutic regimen for PAD consists of antiplatelet agents such as Clopidogrel (Plavix) and Ticlopidine (Ticlid). Blood thinners such as Pentoxifyline (Trental) and Cilostazol (Pletal) are also prescribed. As with most cardiovascular complications Asprin is used as a complementary drug in combination with the above mentioned drugs. The PAD therapeutics market is dominated by generics. Tablet prices range between $0.75 and $2 depending on the brand. The average annual cost of therapy for PAD therapeutics ranges between $300 and $675. The PAD Therapeutics Market Pipeline is Relatively Weak The market has limited scope for growth due to the presence of generic products and the lack of innovation with respect to better efficacy and safety drug profiles. The developmental pipeline is weak with only 34 molecules in various phases of clinical development. There are 16 first-in-class molecules over all the phases of development. The mechanism of action of 11 drugs was not disclosed by the parent company. Phase III contains three first-in-class molecules. These include platelet aggregation inhibitors and granulocyte and macrophage proliferation and differentiation stimulators and combinational therapies employing molecules with these two mechanisms of action. Phase II contains eight first-in-class molecules. Molecules such as Saproprotein and HGF DNA Plasmid employ novel mechanisms of action. The PAD Therapeutics Market Has High Unmet Needs to be Addressed The PAD therapeutics market has unmet needs in terms of both efficacy and safety. These unmet needs imply that the market is moderately served by the current product options and has wide scope available for new entrants that can capture value from the underserved segments. The efficacy of the present therapeutics is moderate to strong with a couple of therapeutic classes with strong efficacy profiles. The therapeutic interventions for PAD are limited to oral formulations in tablet form. Since the market is dominated by generics the price of drugs is relatively low. Safety is a major concern for this market. The occurrence of bleeding complications such as thrombocytopenia ecchymosis epistaxis hematuria and conjunctival hemorrhage are prevalent among the patient population and there is a need for safer drugs. Apart from these complications nausea vomiting and diarrhea are also significant side effects of the present PAD therapeutics. The need for safer drugs especially with respect to the target population of patients between the ages of 50 and 77 years is the primary unmet need for the PAD therapeutics market. To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=132247&rt=Peripheral-Arterial-Disease-PAD-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: info@bharatbook.com Website: www.bharatbook.com Blog: http://bharatbookresearch.blogspot.com Follow us on twitter: http://twitter.com/3bbharatbook
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Statement from Lawrence Massa, CEO and President, ...
S
VPCI Pioneers 'Virtual GMP Consulting' for FDA Pha...